Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 2/2011

01-02-2011 | Original Paper

The roles of bioactive sphingolipids in resveratrol-induced apoptosis in HL60 acute myeloid leukemia cells

Authors: Zeynep Cakir, Guray Saydam, Fahri Sahin, Yusuf Baran

Published in: Journal of Cancer Research and Clinical Oncology | Issue 2/2011

Login to get access

Abstract

Purpose

Acute promyelocytic leukemia results from a translocation between 15 and 17 chromosomes that produce PML/RARα fusion protein. PML/RARα inhibits differentiation of myeloid precursor cells at stem cell level. Resveratrol is a phytoalexin that exerts cytotoxic effects on cancer cells. Ceramides have crucial roles in cell growth, proliferation, differentiation, drug resistance, and apoptosis. In this study, we examined the possible cytotoxic effects of resveratrol on acute myeloid leukemia cells and determined the roles of ceramide-metabolizing genes in resveratrol-induced apoptosis, in addition to investigating the possibility of increasing the sensitivity of HL60 cells to resveratrol by manipulating sphingolipids.

Methods

Cytotoxic effects of resveratrol, C8:ceramide, PDMP, and SK-1 inhibitor were determined by XTT cell proliferation assay. Changes in caspase-3 enzyme activity and mitochondrial membrane potential (MMP) were measured using caspase-3 colorimetric assay and JC-1 MMP detection kit. Expression levels of ceramide-metabolizing genes were examined by RT-PCR.

Results

The results revealed that manipulations of ceramide metabolism toward generation or accumulation of apoptotic ceramides increased apoptotic effects of resveratrol in HL60 cells, synergistically. More importantly, gene expression analyses revealed that resveratrol-induced apoptosis via increasing expression levels of ceramide-generating genes and decreasing expression levels of antiapoptotic sphingosine kinase-1 and glucosylceramide synthase genes.

Conclusion

These results showed for the first time that increasing intracellular levels of ceramides by biochemical approaches has also increased sensitivity of HL60 cells to resveratrol. We also showed that resveratrol induces apoptosis through manipulating ceramide-metabolizing genes that resulted in the accumulation of ceramides in HL60 cells.
Literature
go back to reference Alcalay M, Zangrilli D, Fagioli M, Pandolfi PP, Mencarelli A, Lo Coco F, Biondi A, Grignani F, Pelicci PG (1992) Expression pattern of the RAR alpha-PML fusion gene in acute promyelocytic leukemia. Proc Natl Acad Sci USA 89:4840–4844CrossRefPubMed Alcalay M, Zangrilli D, Fagioli M, Pandolfi PP, Mencarelli A, Lo Coco F, Biondi A, Grignani F, Pelicci PG (1992) Expression pattern of the RAR alpha-PML fusion gene in acute promyelocytic leukemia. Proc Natl Acad Sci USA 89:4840–4844CrossRefPubMed
go back to reference Baran Y, Salas A, Senkal CE, Gunduz U, Bielawski J, Obeid LM, Ogretmen B (2007) Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells. J Biol Chem 282:10922–10934CrossRefPubMed Baran Y, Salas A, Senkal CE, Gunduz U, Bielawski J, Obeid LM, Ogretmen B (2007) Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells. J Biol Chem 282:10922–10934CrossRefPubMed
go back to reference Baur JA, Sinclair DA (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5:493–506CrossRefPubMed Baur JA, Sinclair DA (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5:493–506CrossRefPubMed
go back to reference Bielawska A, Bielawski J, Szulc ZM, Mayroo N, Liu X, Bai A, Elojeimy S, Rembiesa B, Pierce J, Norris JS, Hannun YA (2008) Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids. Bioorg Med Chem 16:1032–1045CrossRefPubMed Bielawska A, Bielawski J, Szulc ZM, Mayroo N, Liu X, Bai A, Elojeimy S, Rembiesa B, Pierce J, Norris JS, Hannun YA (2008) Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids. Bioorg Med Chem 16:1032–1045CrossRefPubMed
go back to reference Bose R, Kolesnick R (2000) Measurement of ceramide synthase activity. Methods Enzymol 322:378–382CrossRefPubMed Bose R, Kolesnick R (2000) Measurement of ceramide synthase activity. Methods Enzymol 322:378–382CrossRefPubMed
go back to reference Crawford KW, Bittman R, Chun J, Byun HS, Bowen WD (2003) Novel ceramide analogues display selective cytotoxicity in drug-resistant breast tumor cell lines compared to normal breast epithelial cells. Cell Mol Biol (Noisy-le-grand) 49:1017–1023 Crawford KW, Bittman R, Chun J, Byun HS, Bowen WD (2003) Novel ceramide analogues display selective cytotoxicity in drug-resistant breast tumor cell lines compared to normal breast epithelial cells. Cell Mol Biol (Noisy-le-grand) 49:1017–1023
go back to reference Dagan A, Wang C, Fibach E, Gatt S (2003) Synthetic, non-natural sphingolipid analogs inhibit the biosynthesis of cellular sphingolipids, elevate ceramide and induce apoptotic cell death. Biochim Biophys Acta 1633:161–169PubMed Dagan A, Wang C, Fibach E, Gatt S (2003) Synthetic, non-natural sphingolipid analogs inhibit the biosynthesis of cellular sphingolipids, elevate ceramide and induce apoptotic cell death. Biochim Biophys Acta 1633:161–169PubMed
go back to reference D'Mello NP, Childress AM, Franklin DS, Kale SP, Pinswasdi C, Jazwinski SM (1994) Cloning and characterization of LAG1, a longevity-assurance gene in yeast. J Biol Chem 269:15451–15459PubMed D'Mello NP, Childress AM, Franklin DS, Kale SP, Pinswasdi C, Jazwinski SM (1994) Cloning and characterization of LAG1, a longevity-assurance gene in yeast. J Biol Chem 269:15451–15459PubMed
go back to reference French KJ, Upson JJ, Keller SN, Zhuang Y, Yun JK, Smith CD (2006) Antitumor activity of sphingosine kinase inhibitors. J Pharmacol Exp Ther 318:596–603CrossRefPubMed French KJ, Upson JJ, Keller SN, Zhuang Y, Yun JK, Smith CD (2006) Antitumor activity of sphingosine kinase inhibitors. J Pharmacol Exp Ther 318:596–603CrossRefPubMed
go back to reference Gouaze-Andersson V, Cabot MC (2006) Glycosphingolipids and drug resistance. Biochim Biophys Acta 1758:2096–2103CrossRefPubMed Gouaze-Andersson V, Cabot MC (2006) Glycosphingolipids and drug resistance. Biochim Biophys Acta 1758:2096–2103CrossRefPubMed
go back to reference Gucluler G, Baran Y (2009) Docetaxel enhances the cytotoxic effects of imatinib on Philadelphia positive human chronic myeloid leukemia cells. Hematology 14:139–144CrossRefPubMed Gucluler G, Baran Y (2009) Docetaxel enhances the cytotoxic effects of imatinib on Philadelphia positive human chronic myeloid leukemia cells. Hematology 14:139–144CrossRefPubMed
go back to reference Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG et al (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275:218–220CrossRefPubMed Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG et al (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275:218–220CrossRefPubMed
go back to reference Lee SK, Zhang W, Sanderson BJ (2008) Selective growth inhibition of human leukemia and human lymphoblastoid cells by resveratrol via cell cycle arrest and apoptosis induction. J Agric Food Chem 56:7572–7577CrossRefPubMed Lee SK, Zhang W, Sanderson BJ (2008) Selective growth inhibition of human leukemia and human lymphoblastoid cells by resveratrol via cell cycle arrest and apoptosis induction. J Agric Food Chem 56:7572–7577CrossRefPubMed
go back to reference Lengfelder E, Reichert A, Schoch C, Haase D, Haferlach T, Löffler H, Staib P, Heyll A, Seifarth W, Saussele S, Fonatsch C, Gassmann W, Ludwig WD, Hochhaus A, Beelen D, Aul C, Sauerland MC, Heinecke A, Hehlmann R, Wörmann B, Hiddemann W, Büchner T (2000) Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. Leukemia 14:1362–1370CrossRefPubMed Lengfelder E, Reichert A, Schoch C, Haase D, Haferlach T, Löffler H, Staib P, Heyll A, Seifarth W, Saussele S, Fonatsch C, Gassmann W, Ludwig WD, Hochhaus A, Beelen D, Aul C, Sauerland MC, Heinecke A, Hehlmann R, Wörmann B, Hiddemann W, Büchner T (2000) Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. Leukemia 14:1362–1370CrossRefPubMed
go back to reference Liu Y, Wang LL (2008) Mifepristone modulates glucosylceramide synthase expression and reverse multidrug resistance in ovarian cancer cells. Nan Fang Yi Ke Da Xue Xue Bao 28:1727–1730PubMed Liu Y, Wang LL (2008) Mifepristone modulates glucosylceramide synthase expression and reverse multidrug resistance in ovarian cancer cells. Nan Fang Yi Ke Da Xue Xue Bao 28:1727–1730PubMed
go back to reference Liu YY, Han TY, Giuliano AE, Cabot MC (1999) Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells. J Biol Chem 274:1140–1146CrossRefPubMed Liu YY, Han TY, Giuliano AE, Cabot MC (1999) Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells. J Biol Chem 274:1140–1146CrossRefPubMed
go back to reference Lo-Coco F, Ammatuna E (2006) The biology of acute promyelocytic leukemia and its impact on diagnosis and treatment. Hematol Am Soc Hematol Educ Program 156–161:514 Lo-Coco F, Ammatuna E (2006) The biology of acute promyelocytic leukemia and its impact on diagnosis and treatment. Hematol Am Soc Hematol Educ Program 156–161:514
go back to reference Mizutani Y, Kihara A, Igarashi Y (2005) Mammalian Lass6 and its related family members regulate synthesis of specific ceramides. Biochem J 390:263–271CrossRefPubMed Mizutani Y, Kihara A, Igarashi Y (2005) Mammalian Lass6 and its related family members regulate synthesis of specific ceramides. Biochem J 390:263–271CrossRefPubMed
go back to reference Morjani H, Aouali N, Belhoussine R, Veldman RJ, Levade T, Manfait M (2001) Elevation of glucosylceramide in multidrug-resistant cancer cells and accumulation in cytoplasmic droplets. Int J Cancer 94:157–165CrossRefPubMed Morjani H, Aouali N, Belhoussine R, Veldman RJ, Levade T, Manfait M (2001) Elevation of glucosylceramide in multidrug-resistant cancer cells and accumulation in cytoplasmic droplets. Int J Cancer 94:157–165CrossRefPubMed
go back to reference Ogretmen B (2006) Sphingolipids in cancer: regulation of pathogenesis and therapy. FEBS Lett 580:5467–5476CrossRefPubMed Ogretmen B (2006) Sphingolipids in cancer: regulation of pathogenesis and therapy. FEBS Lett 580:5467–5476CrossRefPubMed
go back to reference Ogretmen B, Hannun YA (2004) Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 4:604–616CrossRefPubMed Ogretmen B, Hannun YA (2004) Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 4:604–616CrossRefPubMed
go back to reference Perry DK, Carton J, Shah AK, Meredith F, Uhlinger DJ, Hannun YA (2000) Serine palmitoyltransferase regulates de novo ceramide generation during etoposide-induced apoptosis. J Biol Chem 275:9078–9084CrossRefPubMed Perry DK, Carton J, Shah AK, Meredith F, Uhlinger DJ, Hannun YA (2000) Serine palmitoyltransferase regulates de novo ceramide generation during etoposide-induced apoptosis. J Biol Chem 275:9078–9084CrossRefPubMed
go back to reference Pewzner-Jung Y, Ben-Dor S, Futerman AH (2006) When do Lasses (longevity assurance genes) become CerS (ceramide synthases)?: insights into the regulation of ceramide synthesis. J Biol Chem 281:25001–25005CrossRefPubMed Pewzner-Jung Y, Ben-Dor S, Futerman AH (2006) When do Lasses (longevity assurance genes) become CerS (ceramide synthases)?: insights into the regulation of ceramide synthesis. J Biol Chem 281:25001–25005CrossRefPubMed
go back to reference Phillips DC, Hunt JT, Moneypenny CG, Maclean KH, McKenzie PP, Harris LC, Houghton JA (2007) Ceramide-induced G2 arrest in rhabdomyosarcoma (RMS) cells requires p21Cip1/Waf1 induction and is prevented by MDM2 overexpression. Cell Death Differ 14:1780–1791CrossRefPubMed Phillips DC, Hunt JT, Moneypenny CG, Maclean KH, McKenzie PP, Harris LC, Houghton JA (2007) Ceramide-induced G2 arrest in rhabdomyosarcoma (RMS) cells requires p21Cip1/Waf1 induction and is prevented by MDM2 overexpression. Cell Death Differ 14:1780–1791CrossRefPubMed
go back to reference Riebeling C, Allegood JC, Wang E, Merrill AH Jr, Futerman AH (2003) Two mammalian longevity assurance gene (LAG1) family members, trh1 and trh4, regulate dihydroceramide synthesis using different fatty acyl-CoA donors. J Biol Chem 278:43452–43459CrossRefPubMed Riebeling C, Allegood JC, Wang E, Merrill AH Jr, Futerman AH (2003) Two mammalian longevity assurance gene (LAG1) family members, trh1 and trh4, regulate dihydroceramide synthesis using different fatty acyl-CoA donors. J Biol Chem 278:43452–43459CrossRefPubMed
go back to reference Ruckhaberle E, Karn T, Hanker L, Gatje R, Metzler D, Holtrich U, Kaufmann M, Rody A (2009) Prognostic relevance of glucosylceramide synthase (GCS) expression in breast cancer. J Cancer Res Clin Oncol 135:81–90CrossRefPubMed Ruckhaberle E, Karn T, Hanker L, Gatje R, Metzler D, Holtrich U, Kaufmann M, Rody A (2009) Prognostic relevance of glucosylceramide synthase (GCS) expression in breast cancer. J Cancer Res Clin Oncol 135:81–90CrossRefPubMed
go back to reference Sahin F, Avcı CB, Avcu F, Ural AU, Sarper M, Hisil Y, Omay SB, Saydam G (2007) Red grape seed extract and its compound resveratrol exert cytotoxic effect to various human cancer lines. Turk J Hematol 24(3):102–109 Sahin F, Avcı CB, Avcu F, Ural AU, Sarper M, Hisil Y, Omay SB, Saydam G (2007) Red grape seed extract and its compound resveratrol exert cytotoxic effect to various human cancer lines. Turk J Hematol 24(3):102–109
go back to reference Schenck M, Carpinteiro A, Grassme H, Lang F, Gulbins E (2007) Ceramide: physiological and pathophysiological aspects. Arch Biochem Biophys 462:171–175CrossRefPubMed Schenck M, Carpinteiro A, Grassme H, Lang F, Gulbins E (2007) Ceramide: physiological and pathophysiological aspects. Arch Biochem Biophys 462:171–175CrossRefPubMed
go back to reference Senchenkov A, Litvak DA, Cabot MC (2001) Targeting ceramide metabolism—a strategy for overcoming drug resistance. J Natl Cancer Inst 93:347–357CrossRefPubMed Senchenkov A, Litvak DA, Cabot MC (2001) Targeting ceramide metabolism—a strategy for overcoming drug resistance. J Natl Cancer Inst 93:347–357CrossRefPubMed
go back to reference Senkal CE, Ponnusamy S, Rossi MJ, Sundararaj K, Szulc Z, Bielawski J, Bielawska A, Meyer M, Cobanoglu B, Koybasi S et al (2006) Potent antitumor activity of a novel cationic pyridinium-ceramide alone or in combination with gemcitabine against human head and neck squamous cell carcinomas in vitro and in vivo. J Pharmacol Exp Ther 317:1188–1199CrossRefPubMed Senkal CE, Ponnusamy S, Rossi MJ, Sundararaj K, Szulc Z, Bielawski J, Bielawska A, Meyer M, Cobanoglu B, Koybasi S et al (2006) Potent antitumor activity of a novel cationic pyridinium-ceramide alone or in combination with gemcitabine against human head and neck squamous cell carcinomas in vitro and in vivo. J Pharmacol Exp Ther 317:1188–1199CrossRefPubMed
go back to reference Struckhoff AP, Bittman R, Burow ME, Clejan S, Elliott S, Hammond T, Tang Y, Beckman BS (2004) Novel ceramide analogs as potential chemotherapeutic agents in breast cancer. J Pharmacol Exp Ther 309:523–532CrossRefPubMed Struckhoff AP, Bittman R, Burow ME, Clejan S, Elliott S, Hammond T, Tang Y, Beckman BS (2004) Novel ceramide analogs as potential chemotherapeutic agents in breast cancer. J Pharmacol Exp Ther 309:523–532CrossRefPubMed
go back to reference Szulc ZM, Bielawski J, Gracz H, Gustilo M, Mayroo N, Hannun YA, Obeid LM, Bielawska A (2006) Tailoring structure-function and targeting properties of ceramides by site-specific cationization. Bioorg Med Chem 14:7083–7104CrossRefPubMed Szulc ZM, Bielawski J, Gracz H, Gustilo M, Mayroo N, Hannun YA, Obeid LM, Bielawska A (2006) Tailoring structure-function and targeting properties of ceramides by site-specific cationization. Bioorg Med Chem 14:7083–7104CrossRefPubMed
go back to reference Taha TA, Hannun YA, Obeid LM (2006) Sphingosine kinase: biochemical and cellular regulation and role in disease. J Biochem Mol Biol 39:113–131PubMed Taha TA, Hannun YA, Obeid LM (2006) Sphingosine kinase: biochemical and cellular regulation and role in disease. J Biochem Mol Biol 39:113–131PubMed
go back to reference Venkataraman K, Riebeling C, Bodennec J, Riezman H, Allegood JC, Sullards MC, Merrill AH Jr, Futerman AH (2002) Upstream of growth and differentiation factor 1 (uog1), a mammalian homolog of the yeast longevity assurance gene 1 (LAG1), regulates N-stearoyl-sphinganine (C18-(dihydro)ceramide) synthesis in a fumonisin B1-independent manner in mammalian cells. J Biol Chem 277:35642–35649CrossRefPubMed Venkataraman K, Riebeling C, Bodennec J, Riezman H, Allegood JC, Sullards MC, Merrill AH Jr, Futerman AH (2002) Upstream of growth and differentiation factor 1 (uog1), a mammalian homolog of the yeast longevity assurance gene 1 (LAG1), regulates N-stearoyl-sphinganine (C18-(dihydro)ceramide) synthesis in a fumonisin B1-independent manner in mammalian cells. J Biol Chem 277:35642–35649CrossRefPubMed
go back to reference Visentin B, Vekich JA, Sibbald BJ, Cavalli AL, Moreno KM, Matteo RG, Garland WA, Lu Y, Yu S, Hall HS et al (2006) Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell 9:225–238CrossRefPubMed Visentin B, Vekich JA, Sibbald BJ, Cavalli AL, Moreno KM, Matteo RG, Garland WA, Lu Y, Yu S, Hall HS et al (2006) Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell 9:225–238CrossRefPubMed
go back to reference Vitoux D, Nasr R, de The H (2007) Acute promyelocytic leukemia: new issues on pathogenesis and treatment response. Int J Biochem Cell Biol 39:1063–1070CrossRefPubMed Vitoux D, Nasr R, de The H (2007) Acute promyelocytic leukemia: new issues on pathogenesis and treatment response. Int J Biochem Cell Biol 39:1063–1070CrossRefPubMed
go back to reference Weinmann A, Galle PR, Teufel A (2005) LASS6, an additional member of the longevity assurance gene family. Int J Mol Med 16:905–910PubMed Weinmann A, Galle PR, Teufel A (2005) LASS6, an additional member of the longevity assurance gene family. Int J Mol Med 16:905–910PubMed
go back to reference Wieder T, Orfanos CE, Geilen CC (1998) Induction of ceramide-mediated apoptosis by the anticancer phospholipid analog, hexadecylphosphocholine. J Biol Chem 273:11025–11031CrossRefPubMed Wieder T, Orfanos CE, Geilen CC (1998) Induction of ceramide-mediated apoptosis by the anticancer phospholipid analog, hexadecylphosphocholine. J Biol Chem 273:11025–11031CrossRefPubMed
go back to reference Xie P, Shen YF, Shi YP, Ge SM, Gu ZH, Wang J, Mu HJ, Zhang B, Qiao WZ, Xie KM (2008) Overexpression of glucosylceramide synthase in associated with multidrug resistance of leukemia cells. Leuk Res 32:475–480CrossRefPubMed Xie P, Shen YF, Shi YP, Ge SM, Gu ZH, Wang J, Mu HJ, Zhang B, Qiao WZ, Xie KM (2008) Overexpression of glucosylceramide synthase in associated with multidrug resistance of leukemia cells. Leuk Res 32:475–480CrossRefPubMed
go back to reference Xu Z, Zhou J, McCoy DM, Mallampalli RK (2005) LASS5 is the predominant ceramide synthase isoform involved in de novo sphingolipid synthesis in lung epithelia. J Lipid Res 46:1229–1238CrossRefPubMed Xu Z, Zhou J, McCoy DM, Mallampalli RK (2005) LASS5 is the predominant ceramide synthase isoform involved in de novo sphingolipid synthesis in lung epithelia. J Lipid Res 46:1229–1238CrossRefPubMed
go back to reference Zhang P, Liu B, Jenkins GM, Hannun YA, Obeid LM (1997) Expression of neutral sphingomyelinase identifies a distinct pool of sphingomyelin involved in apoptosis. J Biol Chem 272:9609–9612CrossRefPubMed Zhang P, Liu B, Jenkins GM, Hannun YA, Obeid LM (1997) Expression of neutral sphingomyelinase identifies a distinct pool of sphingomyelin involved in apoptosis. J Biol Chem 272:9609–9612CrossRefPubMed
Metadata
Title
The roles of bioactive sphingolipids in resveratrol-induced apoptosis in HL60 acute myeloid leukemia cells
Authors
Zeynep Cakir
Guray Saydam
Fahri Sahin
Yusuf Baran
Publication date
01-02-2011
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 2/2011
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-010-0884-x

Other articles of this Issue 2/2011

Journal of Cancer Research and Clinical Oncology 2/2011 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.